<DOC>
	<DOCNO>NCT00634634</DOCNO>
	<brief_summary>Letrozole aromatase inhibitor approve first-line treatment postmenopausal woman hormone receptor-positive hormone receptor unknown locally advanced metastatic breast cancer . Sorafenib may stop growth tumor cell block blood flow tumor block enzyme need cell growth . This phase I/II trial study side effect best dose sorafenib give combination letrozole see well work treat postmenopausal woman metastatic breast cancer .</brief_summary>
	<brief_title>Phase I/II Trial Letrozole Sorafenib Post-Menopausal Hormone-Receptor + Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically confirm invasive breast cancer 2 . Stage IIIB , IIIC T4 lesion Stage IV disease 3 . Breast cancer must ERpositive and/or PRpositive 4 . Age Â³ 18 year age 5 . ECOG performance status 0 , 1 2 6 . Able swallow oral medication 7 . Adequate end organ function 8 . Written inform consent 1 . Prior hormonal therapy metastatic disease 2 . Prior chemotherapy metastatic disease 3 . Prior treatment sorafenib 4 . Brain metastasis leptomeningeal disease 5 . Evidence history bleed 6 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>Postmenopausal Women Hormone Receptor-Positive Locally Advanced Breast Cancer</keyword>
</DOC>